# EDGAR Filing Document

**Accession Number:** 0001845337
**File Stem:** 0001193125-26-098851
**Filing Date:** 2026-3
**Character Count:** 38407
**Document Hash:** 3f384bf923931f466a0006f5421dcb83
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-098851.hdr.sgml**: 20260309

**ACCESSION NUMBER**: 0001193125-26-098851

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260106

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260309

**DATE AS OF CHANGE**: 20260309

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Day One Biopharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001845337
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832415215
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40431
- **FILM NUMBER:** 26736283

**BUSINESS ADDRESS:**
- **STREET 1:** 1800 SIERRA POINT PARKWAY, SUITE 200
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
- **BUSINESS PHONE:** 650 484-0899

**MAIL ADDRESS:**
- **STREET 1:** 1800 SIERRA POINT PARKWAY, SUITE 200
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Day One Biopharmaceuticals Holding Co LLC
- **DATE OF NAME CHANGE:** 20210209

?xml version='1.0' encoding='ASCII'? 8-K/A

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549** ___________________________

**FORM** 8-K/A

___________________________

**(AMENDMENT NO. 1) CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** January 06, 2026

___________________________

DAY ONE BIOPHARMACEUTICALS, INC.**(Exact name of Registrant as Specified in Its Charter)** ___________________________

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Delaware | &nbsp;&nbsp;001-40431 | &nbsp;&nbsp;83-2415215 |
| &nbsp;&nbsp;**(State or Other Jurisdiction<br>of Incorporation)** | &nbsp;&nbsp;**(Commission File Number)** | &nbsp;&nbsp;**(IRS Employer<br>Identification No.)** |
| &nbsp;&nbsp;1800 Sierra Point Parkway**,** Suite 200Brisbane**,** California |  | &nbsp;&nbsp;94005 |
| &nbsp;&nbsp;**(Address of Principal Executive Offices)** |  | &nbsp;&nbsp;**(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (650) 484-0899

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

___________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | DAWN | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Explanatory Note**

This Amendment No. 1 on Form 8-K/A (this "<u>Amendment No. 1</u>") amends the Current Report on Form 8-K filed by Day One Biopharmaceuticals, Inc. ("<u>Parent</u>") on January 6, 2026 (the "<u>Original Report</u>"), in which Parent reported, among other events, the completion of the Merger (as defined in the Original Report). This Amendment No. 1 is filed to (i) update the information in Item 9.01(a) of the Original Report to include the audited consolidated financial statements of Target (as defined in the Original Report) as of and for the years ended December 31, 2024 and December 31, 2023 and to include the unaudited interim condensed consolidated financial statements of Target as of and for the three and nine months ended September 30, 2025; and (ii) update the information in Item 9.01(b) of the Original Report to include the unaudited pro forma condensed combined financial information of Parent and Target (collectively, the "<u>Company</u>") as of and for the nine months ended September 30, 2025 and the year ended December 31, 2024. This Amendment No. 1 does not amend any other item of the Original Report or purport to provide an update or a discussion of any developments at the Company subsequent to the filing date of the Original Report.

Capitalized terms used but not defined herein have the meanings given to them in the Original Report.

In accordance with Rule 12b-15 of the Securities Exchange Act of 1934, as amended, the complete text of Item 9.01 (as amended) is included herein.

**Item 9.01 Financial Statements and Exhibits.**

(a) Financial Statements of Business Acquired

The audited consolidated financial statements of Target as of and for the years ended December 31, 2024 and December 31, 2023 and the related notes thereto have been audited by Ernst & Young LLP, Target's independent auditor, as set forth in its reports thereon, are incorporated herein by reference as Exhibit 99.1 and Exhibit 99.2, respectively.

The unaudited interim condensed consolidated financial statements of Target as of and for the three and nine months ended September 30, 2025 and the related notes thereto are incorporated herein by reference as Exhibit 99.3.

(b) Pro Forma Financial Information

The unaudited pro forma condensed combined financial information of the Company as of and for the nine months ended September 30, 2025 and the year ended December 31, 2024 is attached hereto as Exhibit 99.4 and incorporated herein by reference.

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 2.1# | [<u>Agreement and Plan of Merger, dated November 12, 2025, by and among Mersana Therapeutics, Inc., Day One Biopharmaceuticals, Inc., and Emerald Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K (File No. 001-38129) filed by Mersana Therapeutics, Inc. with the Securities and Exchange Commission on November 13, 2025)</u>](https://www.sec.gov/Archives/edgar/data/1442836/000110465925110764/tm2531148d1_ex2-1.htm) |
| 10.1 | [<u>Contingent Value Rights Agreement, dated as of January 6, 2026, by and between Day One Biopharmaceuticals, Inc. and Computershare Inc. (previously filed with the Original Report)</u>](https://www.sec.gov/Archives/edgar/data/1845337/000110465926001127/tm261757d1_ex10-1.htm) |
| 23.1 | [<u>Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm</u>](dawn-ex23_1.htm) |
| 99.1 | [<u>Audited Consolidated Financial Statements of Mersana Therapeutics, Inc. and its consolidated subsidiary as of and for the year ended December 31, 2024, the related notes thereto and the report of Ernst & Young LLP (incorporated by reference to Part II, Item 8 of the Annual Report on Form 10-K of Mersana</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001442836/000162828025009246/mrsn-20241231.htm) |

---

------

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
|  | [<u>Therapeutics, Inc. for the year ended December 31, 2024, filed with the SEC on March 3, 2025 (File No. 001-38129))</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001442836/000162828025009246/mrsn-20241231.htm) |
| 99.2 | [<u>Audited Consolidated Financial Statements of Mersana Therapeutics, Inc. and its consolidated subsidiary as of and for the year ended December 31, 2023, the related notes thereto and the report of Ernst & Young LLP (incorporated by reference to Part II, Item 8 of the Annual Report on Form 10-K of Mersana Therapeutics, Inc. for the year ended December 31, 2023, filed with the SEC on February 28, 2024 (File No. 001-38129))</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001442836/000162828024007407/mrsn-20231231.htm) |
| 99.3 | [<u>Unaudited Interim Condensed Consolidated Financial Statements of Mersana Therapeutics, Inc. and its consolidated subsidiary as of and for the three and nine months ended September 30, 2025 and the related notes thereto (incorporated by reference to Part I, Item 1 of the Quarterly Report on Form 10-Q of Mersana Therapeutics, Inc. for the quarter ended September 30, 2025, filed with the SEC on November 14, 2025 (File No. 001-38129))</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001442836/000162828025052202/mrsn-20250930.htm) |
| 99.4 | [<u>Unaudited Pro Forma Condensed Combined Financial Information of Day One Biopharmaceuticals, Inc. as of and for the nine months ended September 30, 2025 and the year ended December 31, 2024</u>](dawn-ex99_4.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

______________

# Certain annexes, exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplemental copies of any of the omitted annexes and schedules upon request by the SEC.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **DAY ONE BIOPHARMACEUTICALS, INC.** | **DAY ONE BIOPHARMACEUTICALS, INC.** |
| Date: March 9, 2026 | By:  | */s/ Charles N. York II, M.B.A.* |
|  |  | Charles N. York II, M.B.A.<br>*Chief Operating Officer and Chief Financial Officer* |

---

------

## Exhibit 23.1

Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm

We consent to the incorporation by reference in Registration Statements on Form S-8 (Nos. 333-256521, 333-263343, 333-268071, 333-269727, 333-276372, and 333-284210) and Form S-3 (Nos. 333-274521 and 333-281822) of Day One Biopharmaceuticals, Inc. of our report dated March 3, 2025, relating to the consolidated financial statements of Mersana Therapeutics, Inc. as of December 31, 2024 and 2023, and for each of the two years in the period ended December 31, 2024, as incorporated by reference in this Current Report on Form 8-K/A of Day One Biopharmaceuticals, Inc.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 9, 2026

------

## Exhibit 99.4

**UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION**

On January 6, 2026, or the Closing Date, Day One Biopharmaceuticals, Inc., or the Company or Day One, completed the acquisition, or Acquisition, of Mersana Therapeutics, Inc., or Mersana. The following unaudited pro forma condensed combined statements of operations (pro forma statements of operations) and condensed combined balance sheet (pro forma balance sheet) give effect to the Acquisition, described in Note 1, and were prepared in accordance with the requirements of Article 11 of Regulation S-X.

The unaudited pro forma condensed combined financial information gives effect to the accounting for the Acquisition, including the pro forma adjustments intended to illustrate the estimated effects of the Acquisition, or the Transaction Accounting Adjustments or Adjustments, as defined in Article 11 of Regulation S-X and do not include any revenue and operating synergies or cost savings that may result from the Acquisition. Management is undertaking certain terminations of employees and expects to incur approximately $9.0 million in severance cost. The pro forma balance sheet as of September 30, 2025, combines the historical balance sheet for the Company and Mersana and is presented as if the Acquisition had occurred on September 30, 2025. The pro forma statements of operations for the nine months ended September 30, 2025, and for the year ended December 31, 2024, are presented as if the Acquisition took place as of January 1, 2024.

The following unaudited pro forma condensed combined financial information was prepared in accordance with Article 11 of Regulation S-X using accounting policies in accordance with U.S. Generally Accepted Accounting Principles, or U.S. GAAP. The unaudited pro forma condensed combined financial information (1) was prepared using the acquisition method of accounting pursuant to Accounting Standards Codification 805, Business Combinations, or ASC 805, with the Company being the accounting acquirer, and (2) is based on the Company and Mersana's historical consolidated financial statements, as adjusted, to present the pro forma impact of the Acquisition.

In accordance with ASC 805, the Company used best estimates and assumptions to accurately assign fair value to the tangible assets acquired and liabilities assumed, identifiable intangible assets, consideration associated with the contingent value right, or CVR, and the related income tax impacts as of the Acquisition date. The estimate of the excess purchase price over the fair value of net tangible assets acquired was allocated to identifiable intangible assets and goodwill. The fair values assigned to Mersana's tangible and identifiable intangible assets acquired and liabilities assumed are based on the Company's estimates and assumptions. The estimated fair values of these assets acquired and liabilities assumed are considered preliminary and are based on the information that was available as of the date of the Acquisition. In the opinion of the Company's management, the unaudited pro forma condensed combined financial information includes all material adjustments necessary to be in accordance with Article 11 of Regulation S-X. The Company intends to finalize the acquisition accounting as soon as practicable within the required measurement period, but in no event later than one year following the Closing Date. The Company is not required to, and currently does not intend to, update these pro forma results as presented herein for any of these changes.

The unaudited pro forma condensed combined financial information is presented for informational purposes only. Such information is not necessarily indicative of the operating results or financial position that would have been achieved if the Acquisition had been consummated on the dates indicated, or that the combined company may achieve in future periods.

The following unaudited pro forma condensed combined financial information as of and for the nine months ended September 30, 2025, and for the year ended December 31, 2024, is derived from:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the historical unaudited Condensed Financial Statements and accompanying notes of Day One as of and for the nine months ended September 30, 2025, included in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, as filed with the SEC on November 4, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the historical audited Financial Statements and accompanying notes of Day One as of and for the year ended December 31, 2024, included in its Annual Report on Form 10-K/A for the year ended December 31, 2024, as filed with the SEC on March 6, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the historical unaudited Condensed Consolidated Financial Statements and accompanying notes of Mersana as of and for the nine months ended September 30, 2025, included in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, as filed with the SEC on November 14, 2025; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the historical audited Consolidated Financial Statements and accompanying notes of Mersana as of and for the year ended December 31, 2024, included in its Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 3, 2025.

------

The Company has performed a preliminary review of the accounting policies of Mersana to assess alignment with the Company's accounting policies and U.S. GAAP. Based on this preliminary review, no material differences in accounting policies were identified that would require adjustment to conform to the Company's accounting policies for purposes of the accompanying unaudited pro forma condensed combined financial information. The Company will continue to evaluate the accounting policies as additional information becomes available, and adjustments may be identified in future periods.

All terms defined in this section of the report are used solely for the purposes of this section and do not apply to any other section of this Current Report on Form 8-K/A.

------

**UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET**

**As of September 30, 2025**

**(in thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Day One** | **Mersana** | **Transaction Accounting Adjustments** | **Pro Forma <br>Combined** |
| **Assets** |  |  |  |  |
| Current assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $43277 | $56391 | $81750<br> (a) | $56391 |
|  |  |  | (125027) (b) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 408303 |  | (81750) (a) | 326553 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 16697 | 168 |  | 16865 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | 7061 |  |  | 7061 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 14633 | 3429 | (1289) (c) | 16773 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 489971 | 59988 | (126316) | 423643 |
| Property and equipment, net | 2227 | 163 |  | 2390 |
| Operating lease right-of-use asset | 2450 | 2035 | (2035) (d) | 2450 |
| Intangible assets, net | 18815 |  | 196850<br> (e) | 215665 |
| Goodwill |  |  | 36745<br> (f) | 36745 |
| Deposits and other long-term assets | 317 | 500 |  | 817 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $513780 | $62686 | $105244 | $681710 |
| **Liabilities and stockholders' equity** |  |  |  |  |
| Current liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $5778 | $2393 | $— | $8171 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 48210 | 14813 | 8531<br> (g) | 71554 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of deferred revenue | 2317 | 23770 |  | 26087 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of contingent consideration |  |  | 8300<br> (b) | 8300 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating lease liabilities | 161 | 2293 | (2293) (d) | 161 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 56466 | 43269 | 14538 | 114273 |
| Long-term portion of deferred revenue | 2953 | 78954 |  | 81907 |
| Long-term portion of contingent consideration |  |  | 39700<br> (b) | 39700 |
| Long-term portion of operating lease liabilities | 2732 |  |  | 2732 |
| Other long-term liability | 761 |  |  | 761 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 62912 | 122223 | 54238 | 239373 |
| Commitments and contingencies |  |  |  |  |
| Stockholders' equity: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock | 10 |  | —<br> (h) | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in-capital | 1090914 | 891980 | (891980) (h) | 1090914 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 69 |  |  | 69 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (640125) | (951517) | 951517<br> (h) | (648656) |
|  |  |  | (8531) (g) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 450868 | (59537) | 51006 | 442337 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $513780 | $62686 | $105244 | $681710 |

---

------

**UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS**

**For the nine months ended September 30, 2025**

**(in thousands, except per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Day One** | **Mersana** | **Transaction Accounting Adjustments** | **Pro Forma <br>Combined** |
| Revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Product revenue, net | $102587 | $— |  | $102587 |
| &nbsp;&nbsp;&nbsp;&nbsp;License revenue | 1877 | 16819 |  | 18696 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 104464 | 16819 |  | 121283 |
| Cost and operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of product and license revenue | 11129 |  |  | 11129 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 107187 | 46741 |  | 153928 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 86440 | 22643 | 986<br> (i) | 110069 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring expense |  | 4131 |  | 4131 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost and operating expenses | 204756 | 73515 |  | 279257 |
| Loss from operations | (100292) | (56696) |  | (157974) |
| Non-operating income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment income, net | 14324 | 2575 | (2873) (j) | 14026 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense |  | (1843) |  | (1843) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other expense, net | (76) |  |  | (76) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total non-operating income, net | 14248 | 732 |  | 12107 |
| Loss before income taxes | (86044) | (55964) |  | (145867) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense |  |  | <br> (k) |  |
| Net loss | (86044) | (55964) |  | (145867) |
| Net loss per share - basic | $(0.83) |  |  | $(1.42) |
| Net loss per share - diluted | $(0.83) |  |  | $(1.42) |
| Weighted-average number of common shares used in net loss per share - basic | 103056046 |  |  | 103056046 |
| Weighted-average number of common shares used in net loss per share - diluted | 103056046 |  |  | 103056046 |

---

------

**UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS**

**For the year ended December 31, 2024**

**(in thousands, except per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Day One** | **Mersana** | **Transaction Accounting Adjustments** | **Pro Forma <br>Combined** |
| Revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Product revenue, net | $57217 | $— |  | $57217 |
| &nbsp;&nbsp;&nbsp;&nbsp;License revenue | 73944 | 40497 |  | 114441 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 131161 | 40497 |  | 171658 |
| Cost and operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of product and license revenue | 5279 |  |  | 5279 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 227702 | 73020 | 1484<br> (l) | 302206 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 115450 | 40813 | 8363<br> (i) | 164626 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost and operating expenses | 348431 | 113833 |  | 472111 |
| Loss from operations | (217270) | (73336) |  | (300453) |
| Non-operating income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain from sale of priority review voucher | 108000 |  |  | 108000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment income, net | 19701 | 8436 | (5940) (j) | 22197 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 1217 |  |  | 1217 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense |  | (3874) |  | (3874) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total non-operating income, net | 128918 | 4562 |  | 127540 |
| Loss before income taxes | (88352) | (68774) |  | (172913) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | (7144) | (418) | <br> (k) | (7562) |
| Net loss | (95496) | (69192) |  | (180475) |
| Net loss per share - basic | $(1.02) |  |  | $(1.94) |
| Net loss per share - diluted | $(1.02) |  |  | $(1.94) |
| Weighted-average number of common shares used in net loss per share - basic | 93234195 |  |  | 93234195 |
| Weighted-average number of common shares used in net loss per share - diluted | 93234195 |  |  | 93234195 |

---

------

**NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION**

**1. Description of the Transaction**

On November 12, 2025, Day One and Mersana entered into an Agreement and Plan of Merger, or the Merger Agreement. Pursuant to the Merger Agreement, the Company commenced a tender offer to acquire all of the issued and outstanding shares of common stock of Mersana, or the Target Shares, for (i) $25.00 net per Target Share, payable in cash, without interest, plus (ii) one CVR per Target Share which represents the right to receive milestone payments of up to an aggregate of $30.25 per share in cash upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement.

On January 6, 2026, the transaction closed and the Company acquired all outstanding Target Shares at a price of $25.00 per share in cash, plus one non-tradable CVR per share to receive certain potential milestone payments of up to an aggregate of $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash.

**2. Basis of Presentation**

The unaudited pro forma condensed combined financial statements and related notes are prepared in accordance with Article 11 of Regulation S-X and present the historical financial information of Day One and Mersana, the pro forma effects of the Acquisition and certain acquisition accounting adjustments described herein.

The business combination of Mersana has been accounted for using the acquisition method of accounting as per the provisions of ASC 805, using the fair value concepts defined in ASC Topic 820 – Fair Value Measurement and based on the historical financial statements of Day One and the historical consolidated financial statements of Mersana. Under ASC 805, all assets acquired and liabilities assumed in a business combination are generally recognized and measured at their assumed acquisition date fair value, while transaction costs and restructuring costs associated with the business combination are expensed as incurred. The excess of preliminary purchase price over the fair value of assets acquired and liabilities assumed, has been recorded in goodwill. The pro forma adjustments represent management's best estimates and are based upon information currently available and certain assumptions that the management of Day One believes are reasonable under the circumstances.

The unaudited pro forma financial statements are provided for illustrative purposes only and do not purport to represent what the actual consolidated results of the companies would have been had the Acquisition occurred on the dates indicated, nor are they necessarily indicative of future consolidated results of operations of the Company. The pro forma statements of operations neither reflect the costs of any integration activities, nor the synergies and benefits that may result from realization of any anticipated revenue growth or operational efficiencies expected to result from the Acquisition.

There were no material transactions between Day One and Mersana during the periods presented in the unaudited pro forma condensed combined financial statements.

**3. Preliminary Purchase Price Accounting and Allocation**

*Preliminary purchase price* 

The preliminary purchase price consideration consists of the cash paid and the estimated fair value of the CVRs at the Closing Date as follows (in thousands):

---

| | |
|:---|:---|
| Cash | $125027 |
| Estimated fair value of contingent value rights | 48000 |
| &nbsp;&nbsp;Total estimated fair value of consideration transferred | $173027 |

---

*Preliminary purchase price allocation*

Day One's purchase price allocation for the Acquisition is preliminary and subject to revision as additional information regarding the fair value of the assets acquired and liabilities assumed becomes available. Due to the nature of the tangible assets acquired and liabilities assumed, Day One has determined that the carrying amounts of such assets and liabilities as of the Closing Date approximate their respective fair values. In accordance with ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, the Company has recognized deferred revenue as of the Closing Date, measured in accordance with ASC 606, Revenue from Contracts with Customers.

------

Day One has engaged a third-party valuation specialist to assist in the valuation of the identifiable intangible assets acquired and the consideration associated with the CVR. The preliminary valuation is based on the financial information available as of the Closing Date, consideration of comparable transactions, and currently available, but limited, forecasted financial information. The unaudited pro forma condensed combined financial statements may differ from the Company's final purchase price accounting for a number of reasons, including the fact that the estimates of fair values of assets acquired and liabilities assumed as of the Closing Date are preliminary and therefore subject to change within the measurement period (no longer than one year from the Closing Date), at which time the valuation analysis and other analyses are finalized.<br>

The following table sets forth a preliminary allocation of the estimated purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed as of September 30, 2025, with the excess recorded as goodwill (in thousands):

---

| | |
|:---|:---|
| Cash and cash equivalents | $56391 |
| Accounts receivable | 168 |
| Prepaid expenses and other current assets | 2140 |
| Property and equipment | 163 |
| Deposits and other long-term assets | 500 |
| Intangible assets | 196850 |
| &nbsp;&nbsp;Total assets acquired | $256212 |
| Accounts payable | 2393 |
| Accrued expenses and other current liabilities | 14813 |
| Current and long-term portion of deferred revenue | 102724 |
| &nbsp;&nbsp;Total liabilities assumed | $119930 |
| Net assets acquired | $136282 |
| &nbsp;&nbsp;Total estimated fair value of consideration transferred | 173027 |
| Preliminary goodwill | $36745 |

---

**4. Transaction Accounting Adjustments**

The pro forma adjustments are based on our preliminary estimates and assumptions that are subject to change. The following are the pro forma adjustments included in the unaudited pro forma condensed combined balance sheet as of September 30, 2025 and give effect to the Acquisition as if it had occurred on that date:

(a) Represents the liquidation of $81.8 million of Day One's short-term investments to fund the Acquisition, reflecting the amount of cash that would have been required to be transferred had the Acquisition closed on September 30, 2025. This cash conversion is reflected as a corresponding increase in cash and cash equivalents.

(b) Represents the total purchase consideration of $173.0 million, consisting of cash consideration of $125.0 million and a liability for the preliminary estimated fair value of contingent consideration of $48.0 million ($8.3 million recorded under Contingent consideration, current portion and $39.7 million recorded under Long-term portion of contingent consideration based on estimated timing of potential payments) as of the Closing Date. The potential payments are based on the achievement of (i) regulatory milestones, (ii) commercial milestones and (iii) specified net sales thresholds. The aggregate undiscounted maximum amount of contingent consideration that could become payable under the arrangement is approximately $156.0 million. The Company is not able to reasonably estimate the range of undiscounted outcomes at this time due to significant uncertainties regarding the probability and timing of achieving the specified milestones. These uncertainties include development risk, regulatory approval risk, and the variability of future commercial performance. The contingent consideration is classified as a liability in accordance with ASC 805 and will be remeasured at fair value at each reporting date and subsequent changes in the fair value post-Closing Date will be recognized in the combined statement of operations.

(c) Represents an adjustment of $1.3 million for the directors and officers tail insurance policy required per the terms of the Merger Agreement. The policy covers claims related to pre-Closing Date events and, in accordance with ASC 805, is reflected as a reduction of Mersana's net assets as of the Closing Date, as it relates solely to pre-combination activities and does not represent a post-combination operating asset.

(d) Represents the elimination of the Mersana right-of-use asset and corresponding lease liability. As of the Closing Date, the remaining lease term was less than twelve months and did not include any purchase options. Accordingly, the Company applied the short-term lease recognition exemption and did not recognize a right-of-use asset or lease liability in accordance with ASC 805.

------

(e) Represents the identifiable intangible assets acquired by the Company at the preliminary estimated fair value as of the Closing Date. The identifiable intangible assets consist of a contract-based license asset with a preliminary estimated fair value of $22.4 million and an in-process research and development, or IPR&D, asset with a preliminary estimated fair value of $174.5 million. The contract-based license intangible asset has a preliminary estimated useful life of seventeen years. IPR&D assets are considered indefinite-lived until completion or abandonment of the associated research and development efforts and therefore are not amortized during that period.

(f) Represents the recognition of goodwill resulting from the Acquisition, calculated as the excess of the total consideration transferred over the preliminary estimated fair values of the identifiable tangible and intangible assets acquired and liabilities assumed of Mersana as of September 30, 2025.

(g) Represents direct and incremental expense related to the Acquisition incurred by Day One of $4.8 million for advisory and legal fees payable directly to third party vendors and $3.7 million of employee equity cash settlement obligations related to accelerated vesting of Mersana equity awards as per the Merger Agreement. The Company made these adjustments to accrued liabilities and accumulated deficit as these expenses were recognized subsequent to the Day One September 30, 2025 historical balance sheet presented.

(h) Represents the elimination of Mersana historical equity balances as of September 30, 2025.

The pro forma adjustments are based on our preliminary estimates and assumptions that are subject to change. The following are the pro forma adjustments included in the unaudited pro forma consolidated combined statement of operations for the nine months ended September 30, 2025 and year ended December 31, 2024 giving effect to the Acquisition as if it had occurred on January 1, 2024.

(i) Represents an increase in selling, general and administrative expenses of $1.0 million for the nine months ended September 30, 2025 and $8.4 million for the year ended December 31, 2024. The increase for the nine months ended September 30, 2025 consists of estimated amortization expense related to the finite-lived intangible asset, as described in Note 4(e), calculated on a straight-line basis over the asset's estimated useful life. The increase for the year ended December 31, 2024 consists of (i) $7.1 million of direct and incremental expenses related to the Acquisition incurred by Day One of $4.8 million related to advisory and legal fees payable to third-party vendors and $2.3 million related to employee equity cash settlement obligations that are not reflected in Day One's historical financial information, as described in Note 4(g) and (ii) $1.3 million of estimated amortization expense related to the finite-lived intangible asset, calculated on a straight-line basis over the asset's estimated useful life. The estimated amortization expense is recorded within selling, general and administrative expenses because the contract-based license intangible asset does not require Day One to perform research and development activities and is not associated with an approved product. The advisory and legal fees and the equity cash settlement obligations are nonrecurring in nature and are not expected to have a continuing impact on the combined results.

(j) Represents interest income forgone of $2.9 million for the nine months ended September 30, 2025, and $5.9 million for the year ended December 31, 2024 as a result of the liquidation of $81.8 million of Day One's short-term investments, as described in Note 4(a). The interest income forgone was calculated using the Company's actual average rates of return realized on its investment portfolio during the respective periods presented.

(k) No income tax effect has been reflected for the pro forma transaction accounting adjustments. Mersana has significant net operating loss carryforwards and other deferred tax assets, which are fully offset by a full valuation allowance because future realization is not expected. Consequently, although taxable temporary differences give rise to deferred tax liabilities, no net deferred tax liability is recognized and no current tax benefit or expense was reflected in the periods presented. The accounting for opening balance sheet deferred income taxes is preliminary. The estimates may differ from amounts the Company will calculate after completing a detailed analysis, and the difference could have a material effect on the accompanying unaudited pro forma financial statements. The actual tax impact in periods subsequent to the Acquisition may differ due to changes in the valuation allowance assessment, jurisdictional earnings mix and other discrete items.

(l) Represents an increase in research and development expenses of $1.5 million for the year ended December 31, 2024 for employee equity cash settlement obligations that are not reflected in Day One's historical financial information, as described in Note 4(g).

------